Siponimod (Mayzent®) accepted for use within NHS Scotland for treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease
Approval was based on a randomised, double-blind, placebo-controlled phase III study, which showed siponimod was associated with a reduction in disability progression confirmed after 3 months in patients with SPMS.
Source:
Scottish Medicines Consortium